Organometallic complexes—cancer-fighting compounds built around metal-carbon bonds—are emerging as a more selective alternative to traditional platinum drugs like cisplatin. While platinum treatments remain effective, they often damage healthy cells and quickly lead to resistance. New metal-based designs aim to target cancer more precisely and avoid these limitations.
Cyclometalated complexes are especially promising because their chemistry can be adjusted to help them enter tumors easily and act through new mechanisms. Ruthenium complexes lead the field: some have reached clinical trials and show strong activity against cancer cells while sparing normal tissue. Unlike cisplatin, they often work in the mitochondria or endoplasmic reticulum, helping them bypass common resistance pathways. Many can also be activated by light, becoming far more potent for localized photodynamic therapy.
Researchers are also exploring iron complexes, which take advantage of cancer cells’ high iron demand. These compounds can trigger cell death through stress and autophagy pathways that don’t rely on p53, offering another escape from typical drug resistance.
Overall, organometallic complexes are opening a new chapter in cancer therapy by combining selectivity, versatility, and the ability to overcome resistance.